Pharmacologic Management of Depression‑Related Hypersomnia

First‑Line Wake‑Promoting Agent

The American Academy of Sleep Medicine gives a strong recommendation for using modafinil (100–400 mg each morning) as the first‑line wake‑promoting medication in patients with depression‑associated hypersomnia, based on evidence from clinical sleep‑medicine guidelines. 1

The American Academy of Sleep Medicine provides a conditional recommendation for armodafinil (150–250 mg daily) for central hypersomnolence disorders, including hypersomnia secondary to depression. 2
A conditional recommendation also supports methylphenidate (10–60 mg daily in divided doses) for refractory hypersomnia, with the caveat that it requires careful monitoring because it is a Schedule II controlled substance. 2
Solriamfetol (strong recommendation) and pitolisant (conditional recommendation) are newer agents approved for narcolepsy; they have limited data in depression‑related hypersomnia but may be considered when other agents fail. 4

Low‑sodium oxybate received FDA approval in 2021 for idiopathic hypersomnia and has demonstrated efficacy in reducing daytime sleepiness, decreasing sleep inertia, and improving daily functioning; its use in patients with comorbid depression remains investigational. 3

All wake‑promoting agents and antidepressants carry warnings of potential fetal harm, necessitating pregnancy risk assessment before prescribing. 3
Methylphenidate and low‑sodium oxybate are classified as controlled substances (Schedule II and Schedule III, respectively) and require appropriate documentation and monitoring. 3